Las Vegas NV / May 20, 2015 / (VRCI-OTCQB) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing effective treatments for contemporary health issues, with an initial focus on developing cannabinoid-based prescription medicines is pleased to announce the appointment of Bradley J. Dixon, J.D. to its Board of Directors. Mr. Dixon is a partner with the firm of Stoel Rives, LLP, which has offices throughout the Northwest and California. His professional honors include selection as one of America’s Leading Lawyers for Business by Chambers USA, listing in Mountain States Super Lawyers, and admission to the Order of Barristers. Mr. Dixon’s areas of practice include Business Law, Government Affairs, Commercial Litigation, and Labor and Employment Law.

Verde Science CEO, Harp Sangha commented, “As Verde Science accelerates its development into a more complex international structure with multiple interconnected facets including research and product development, intellectual property, and corporate finance and governance, it has become apparent that participation from legal professionals is a required input for our strategic and tactical decision-making. I am proud and excited to have Brad add his experience in this regard and to be able to benefit from his business and legal acumen.”

“Harp Sangha has assembled a world-class research and development team that seems poised to achieve an eminent position in the medical marijuana field. I am an energetic supporter of their pharmacological approach that avoids numerous regulatory and legal pitfalls. I am honored to be a part of this company,” according to Bradley Dixon.

About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.

For further information please see our investor profile available on our website:

Harp Sangha, Chairman
Tel:        1-604-825-1309

Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.